Drug Trial Radar · NCT07221188
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,250
Planned (sponsor's estimate)
Start
Dec 12, 2025
Primary completion
Mar 24, 2028
Study completion Mar 24, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Conditions
- Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin AlfaDrug
Efimosfermin Alfa will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severityTime frame: At Week 52
- Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severityTime frame: At Week 52
- Number of participants with Grade 3 and Grade 4 laboratory abnormalitiesTime frame: At Week 52
Locations
66 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Arcadia, California · Recruiting
GSK Investigational Site
Covina, California · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
San Diego, California · Recruiting
GSK Investigational Site
Santa Maria, California · Recruiting
GSK Investigational Site
Van Nuys, California · Recruiting
GSK Investigational Site
Boynton Beach, Florida · Recruiting
GSK Investigational Site
Cape Coral, Florida · Recruiting
GSK Investigational Site
Clermont, Florida · Recruiting
GSK Investigational Site
Doral, Florida · Recruiting
GSK Investigational Site
Fort Myers, Florida · Recruiting
GSK Investigational Site
Hialeah, Florida · Recruiting
GSK Investigational Site
Homestead, Florida · Recruiting
GSK Investigational Site
Inverness, Florida · Recruiting
GSK Investigational Site
Jacksonville, Florida · Recruiting
GSK Investigational Site
Kissimmee, Florida · Recruiting
GSK Investigational Site
Lakeland, Florida · Recruiting
GSK Investigational Site
Maitland, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Ocala, Florida · Recruiting
GSK Investigational Site
Palmetto Bay, Florida · Recruiting
GSK Investigational Site
Sarasota, Florida · Recruiting
GSK Investigational Site
Topeka, Kansas · Recruiting
GSK Investigational Site
Marrero, Louisiana · Recruiting
GSK Investigational Site
Springfield, Missouri · Recruiting
GSK Investigational Site
St Louis, Missouri · Recruiting
GSK Investigational Site
St Louis, Missouri · Recruiting
GSK Investigational Site
Jersey City, New Jersey · Recruiting
GSK Investigational Site
East Syracuse, New York · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Morehead City, North Carolina · Recruiting
GSK Investigational Site
Akron, Ohio · Recruiting
GSK Investigational Site
Springboro, Ohio · Recruiting
GSK Investigational Site
Chattanooga, Tennessee · Recruiting
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.